Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Park

Cardiovascular Disease Elgin, IL Medical Doctor

NPI 1568579027 CMS profile 162010

87 N Airlite St, Suite #100, Elgin, IL 60123

Open in the dashboard

General payments

$25,014

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Park of Elgin, IL is reported in the CMS Open Payments database as having received $25,014 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,184 31
2024 General $1,036 25
2023 General $2,808 47
2022 General $5,172 64
2021 General $1,549 33
2020 General $1,406 23
2019 General $11,859 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Park
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Richard Park were reported at $1,184. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Richard Park Cardiovascular Disease median Middle half National median
2019 $11,859 $450 $127–$1,392 $163
2020 $1,406 $242 $77–$751 $114
2021 $1,549 $335 $101–$1,037 $132
2022 $5,172 $395 $121–$1,211 $149
2023 $2,808 $443 $136–$1,283 $160
2024 $1,036 $450 $136–$1,323 $164
2025 $1,184 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $12,389 46 payments
  2. Edwards Lifesciences Corporation $6,020 57 payments
  3. Abbott Laboratories $1,887 57 payments
  4. Boston Scientific Corporation $1,792 35 payments
  5. Medtronic Vascular, Inc. $814 12 payments
  6. Abiomed $430 8 payments
  7. Janssen Pharmaceuticals, Inc $252 5 payments
  8. Cook Medical LLC $197 5 payments
  9. Biotronik Inc. $169 7 payments
  10. E.R. Squibb & Sons, L.L.C. $138 8 payments
  11. Other $925 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,999 243 payments
  2. Honoraria $8,550 2 payments
  3. Travel and Lodging $6,464 26 payments
Products named General payments · program years 2019–2025
  1. EXCLUDER AAA Endoprosthesis $8,569 3 payments
  2. GORE TAG Thoracic Endoprosthesis $1,725 11 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,479 19 payments
  4. Edwards SAPIEN 3 Transcatheter Heart Valve $1,467 11 payments
  5. STINGRAY $1,011 8 payments
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $874 7 payments
  7. GORE TAG Thoracic Branch Endoprosthesis $788 7 payments
  8. GORE TAG Conformable Thoracic Endoprosthesis $757 7 payments
  9. CoreValve Evolut $708 11 payments
  10. SAPIEN 3 Ultra RESILIA $658 8 payments
  11. Other $5,738 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,230

Median for Interventional Cardiology: 2,236

Drug cost

$472,152

Median for Interventional Cardiology: $380,412

Branded share of claims

33.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 213 $244,587
Xarelto Rivaroxaban Brand 84 $94,062
Multaq Dronedarone Hcl Brand 41 $59,810
Entresto Sacubitril/Valsartan Brand 31 $38,879
Repatha Sureclick Evolocumab Brand 13 $10,565
Clopidogrel Clopidogrel Bisulfate Brand 291 $3,441
Metoprolol Succinate Generic 221 $3,340
Diltiazem 12hr Er Diltiazem Hcl Brand 12 $1,644
Carvedilol Generic 117 $1,463
Atorvastatin Calcium Generic 201 $1,419

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$252,948

Medicare's payments for the services billed

Medicare patients

1,139

Average age 77

Services billed

3,037

530 women, 609 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 52%
Arthritis 51%
Chronic kidney disease 40%
Diabetes 38%
Atrial fibrillation 38%
Heart failure 37%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $49
$49 13 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $28
$28 — —
ELIQUIS
  • PFIZER INC. $20
$20 213 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record